Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q6P2C8

UPID:
MED27_HUMAN

ALTERNATIVE NAMES:
Cofactor required for Sp1 transcriptional activation subunit 8; Mediator complex subunit 27; P37 TRAP/SMCC/PC2 subunit; Transcriptional coactivator CRSP34

ALTERNATIVE UPACC:
Q6P2C8; O95401; Q4F964; Q5VTA4; Q5VTA5; Q9BU57; Q9NYR4; V9GYV9

BACKGROUND:
The Mediator of RNA polymerase II transcription subunit 27, known by alternative names such as Cofactor required for Sp1 transcriptional activation subunit 8, is a crucial component of the Mediator complex. This complex is essential for the transcription of RNA polymerase II-dependent genes, serving as a scaffold for regulatory protein interactions and preinitiation complex assembly.

THERAPEUTIC SIGNIFICANCE:
Given its association with a neurodevelopmental disorder characterized by developmental delay, impaired intellectual development, and cerebellar hypoplasia, targeting Mediator of RNA polymerase II transcription subunit 27 could offer new avenues for therapeutic intervention in such genetic conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.